Twenty years of therapy for HIV-1 infection. (Q53382316)

13 May 2018

title

Twenty years of therapy for HIV-1 infection. (English)

1 reference

13 May 2018

0 references

1

Roger J Pomerantz

1 reference

13 May 2018

author name string

David L Horn

series ordinal

2

1 reference

13 May 2018

language of work or name

English

0 references

publication date

1 July 2003

1 reference

13 May 2018

published in

Nature Medicine

1 reference

13 May 2018

volume

9

1 reference

13 May 2018

page(s)

867-873

1 reference

13 May 2018

issue

7

1 reference

13 May 2018

https://scigraph.springernature.com/pub.10.1038/nm0703-867

exact match

0 references

cites work

Survival with the acquired immunodeficiency syndrome. Experience with 5833 cases in New York City

1 reference

https://api.crossref.org/works/10.1038%2FNM0703-867

7 January 2021

Isolation of a T-Lymphotropic Retrovirus from a Patient at Risk for Acquired Immune Deficiency Syndrome (AIDS)

1 reference

https://api.crossref.org/works/10.1038%2FNM0703-867

7 January 2021

Isolation of human T-cell leukemia virus in acquired immune deficiency syndrome (AIDS)

1 reference

https://api.crossref.org/works/10.1038%2FNM0703-867

7 January 2021

AIDS drug gets green light

1 reference

https://api.crossref.org/works/10.1038%2FNM0703-867

7 January 2021

https://api.crossref.org/works/10.1038%2FNM0703-867

1 reference

7 January 2021

https://api.crossref.org/works/10.1038%2FNM0703-867

1 reference

7 January 2021

A comparison of immediate with deferred zidovudine therapy for asymptomatic HIV-infected adults with CD4 cell counts of 500 or more per cubic millimeter. AIDS Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1038%2FNM0703-867

7 January 2021

Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group

1 reference

https://api.crossref.org/works/10.1038%2FNM0703-867

7 January 2021

Inhibition of HIV by an anti-HIV protease synthetic peptide blocks an early step of viral replication

1 reference

https://api.crossref.org/works/10.1038%2FNM0703-867

7 January 2021

L-735,524: the design of a potent and orally bioavailable HIV protease inhibitor

1 reference

https://api.crossref.org/works/10.1038%2FNM0703-867

7 January 2021

L-735,524: an orally bioavailable human immunodeficiency virus type 1 protease inhibitor

1 reference

https://api.crossref.org/works/10.1038%2FNM0703-867

7 January 2021

A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team

1 reference

https://api.crossref.org/works/10.1038%2FNM0703-867

7 January 2021

A randomized, controlled trial of indinavir, zidovudine, and lamivudine in adults with advanced human immunodeficiency virus type 1 infection and prior antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1038%2FNM0703-867

7 January 2021

3-year suppression of HIV viremia with indinavir, zidovudine, and lamivudine

1 reference

https://api.crossref.org/works/10.1038%2FNM0703-867

7 January 2021

Initiation of highly active antiretroviral therapy at CD4+ T lymphocyte counts of >350 cells/mm3: disease progression, treatment durability, and drug toxicity

1 reference

https://api.crossref.org/works/10.1038%2FNM0703-867

7 January 2021

Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection

1 reference

https://api.crossref.org/works/10.1038%2FNM0703-867

7 January 2021

Viral dynamics in human immunodeficiency virus type 1 infection

1 reference

https://api.crossref.org/works/10.1038%2FNM0703-867

7 January 2021

Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection

1 reference

https://api.crossref.org/works/10.1038%2FNM0703-867

7 January 2021

Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team

1 reference

https://api.crossref.org/works/10.1038%2FNM0703-867

7 January 2021

A short-term clinical evaluation of L-697,661, a non-nucleoside inhibitor of HIV-1 reverse transcriptase. L-697,661 Working Group

1 reference

https://api.crossref.org/works/10.1038%2FNM0703-867

7 January 2021

A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome.

1 reference

https://api.crossref.org/works/10.1038%2FNM0703-867

7 January 2021

Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study

1 reference

https://api.crossref.org/works/10.1038%2FNM0703-867

7 January 2021

Fat distribution and metabolic changes in patients with HIV infection

1 reference

https://api.crossref.org/works/10.1038%2FNM0703-867

7 January 2021

A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FNM0703-867

7 January 2021

Non-adherence to highly active antiretroviral therapy predicts progression to AIDS.

1 reference

https://api.crossref.org/works/10.1038%2FNM0703-867

7 January 2021

Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population.

1 reference

https://api.crossref.org/works/10.1038%2FNM0703-867

7 January 2021

Open-label study of a twice-daily indinavir 800-mg/ritonavir 100-mg regimen in protease inhibitor-naive HIV-infected adults

1 reference

https://api.crossref.org/works/10.1038%2FNM0703-867

7 January 2021

Pharmacokinetics of once-daily saquinavir hard-gelatin capsules and saquinavir soft-gelatin capsules boosted with ritonavir in HIV-1-infected subjects

1 reference

https://api.crossref.org/works/10.1038%2FNM0703-867

7 January 2021

Lopinavir/ritonavir: a review of its use in the management of HIV infection

1 reference

https://api.crossref.org/works/10.1038%2FNM0703-867

7 January 2021

Highly active antiretroviral therapy: pharmacoeconomic issues in the management of HIV infection

1 reference

https://api.crossref.org/works/10.1038%2FNM0703-867

7 January 2021

Strategies for long-term success in the treatment of HIV infection

1 reference

https://api.crossref.org/works/10.1038%2FNM0703-867

7 January 2021

Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA Panel.

1 reference

https://api.crossref.org/works/10.1038%2FNM0703-867

7 January 2021

Genotypic testing for human immunodeficiency virus type 1 drug resistance

1 reference

https://api.crossref.org/works/10.1038%2FNM0703-867

7 January 2021

Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial.

1 reference

https://api.crossref.org/works/10.1038%2FNM0703-867

7 January 2021

A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. CPCRA 046 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS.

1 reference

https://api.crossref.org/works/10.1038%2FNM0703-867

7 January 2021

Primary HIV-1 resistance: a new phase in the epidemic?

1 reference

https://api.crossref.org/works/10.1038%2FNM0703-867

7 January 2021

Antiretroviral-drug resistance among patients recently infected with HIV.

1 reference

https://api.crossref.org/works/10.1038%2FNM0703-867

7 January 2021

Predominance of Distinct Viral Genotypes in Brain and Lymph Node Compartments of HIV-1-Infected Individuals

1 reference

https://api.crossref.org/works/10.1038%2FNM0703-867

7 January 2021

1 reference

https://api.crossref.org/works/10.1038%2FNM0703-867

7 January 2021

Human immunodeficiency virus type 1 in the semen of men receiving highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1038%2FNM0703-867

7 January 2021

Recovery of replication-competent HIV despite prolonged suppression of plasma viremia

1 reference

https://api.crossref.org/works/10.1038%2FNM0703-867

7 January 2021

Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1038%2FNM0703-867

7 January 2021

Residual HIV-1 infection during antiretroviral therapy: the challenge of viral persistence

1 reference

https://api.crossref.org/works/10.1038%2FNM0703-867

7 January 2021

Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1038%2FNM0703-867

7 January 2021

Human immunodeficiency virus type 1-infected persons with residual disease and virus reservoirs on suppressive highly active antiretroviral therapy can be stratified into relevant virologic and immunologic subgroups

1 reference

https://api.crossref.org/works/10.1038%2FNM0703-867

7 January 2021

Intensification and stimulation therapy for human immunodeficiency virus type 1 reservoirs in infected persons receiving virally suppressive highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1038%2FNM0703-867

7 January 2021

Approaching eradication of highly active antiretroviral therapy-persistent human immunodeficiency virus type 1 reservoirs with immune activation therapy.

1 reference

https://api.crossref.org/works/10.1038%2FNM0703-867

7 January 2021

Reservoirs of human immunodeficiency virus type 1: the main obstacles to viral eradication

1 reference

https://api.crossref.org/works/10.1038%2FNM0703-867

7 January 2021

Long-lasting recovery in CD4 T-cell function and viral-load reduction after highly active antiretroviral therapy in advanced HIV-1 disease

1 reference

https://api.crossref.org/works/10.1038%2FNM0703-867

7 January 2021

Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease

1 reference

https://api.crossref.org/works/10.1038%2FNM0703-867

7 January 2021

Time to hit HIV, early and hard.

1 reference

https://api.crossref.org/works/10.1038%2FNM0703-867

7 January 2021

Survival Benefit of Initiating Antiretroviral Therapy in HIV-Infected Persons in Different CD4+ Cell Strata

1 reference

https://api.crossref.org/works/10.1038%2FNM0703-867

7 January 2021

Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America

1 reference

https://api.crossref.org/works/10.1038%2FNM0703-867

7 January 2021

Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry

1 reference

https://api.crossref.org/works/10.1038%2FNM0703-867

7 January 2021

The safety, plasma pharmacokinetics, and antiviral activity of subcutaneous enfuvirtide (T-20), a peptide inhibitor of gp41-mediated virus fusion, in HIV-infected adults.

1 reference

https://api.crossref.org/works/10.1038%2FNM0703-867

7 January 2021

New antiretroviral drugs

1 reference

https://api.crossref.org/works/10.1038%2FNM0703-867

7 January 2021

The Major Infectious Diseases in the World — To Treat or Not to Treat?

1 reference

https://api.crossref.org/works/10.1038%2FNM0703-867

7 January 2021

The care of HIV-infected adults in the United States. HIV Cost and Services Utilization Study Consortium.

1 reference

https://api.crossref.org/works/10.1038%2FNM0703-867

7 January 2021

Estimating the national cost of treating people with HIV disease: patient, payer, and provider data

1 reference

https://api.crossref.org/works/10.1038%2FNM0703-867

7 January 2021

Structured Treatment Interruption: Approaches and Risks

1 reference

https://api.crossref.org/works/10.1038%2FNM0703-867

7 January 2021

The virological and immunological consequences of structured treatment interruptions in chronic HIV-1 infection

1 reference

https://api.crossref.org/works/10.1038%2FNM0703-867

7 January 2021

Sustained peptide-specific gamma interferon T-cell response in rhesus macaques immunized with human immunodeficiency virus gag DNA vaccines

1 reference

https://api.crossref.org/works/10.1038%2FNM0703-867

7 January 2021

Studies in subjects with long-term nonprogressive human immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1038%2FNM0703-867

7 January 2021

Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia

1 reference

https://api.crossref.org/works/10.1038%2FNM0703-867

7 January 2021

HIV-1: fifteen proteins and an RNA

1 reference

https://api.crossref.org/works/10.1038%2FNM0703-867

7 January 2021

Diketo acid inhibitor mechanism and HIV-1 integrase: implications for metal binding in the active site of phosphotransferase enzymes

1 reference

https://api.crossref.org/works/10.1038%2FNM0703-867

7 January 2021

A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity

1 reference

https://api.crossref.org/works/10.1038%2FNM0703-867

7 January 2021

AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor.

1 reference

https://api.crossref.org/works/10.1038%2FNM0703-867

7 January 2021

New anti-HIV agents and targets

1 reference

https://api.crossref.org/works/10.1038%2FNM0703-867

7 January 2021

Potent suppression of viral infectivity by the peptides that inhibit multimerization of human immunodeficiency virus type 1 (HIV-1) Vif proteins

1 reference

https://api.crossref.org/works/10.1038%2FNM0703-867

7 January 2021

Comprehensive investigation of the molecular defect in vif-deficient human immunodeficiency virus type 1 virions

1 reference

https://api.crossref.org/works/10.1038%2FNM0703-867

7 January 2021

Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein

1 reference

https://api.crossref.org/works/10.1038%2FNM0703-867

7 January 2021

Inhibition of human immunodeficiency virus type 1 (HIV-1) replication by a two-amino-acid insertion in HIV-1 Vif from a nonprogressing mother and child

1 reference

https://api.crossref.org/works/10.1038%2FNM0703-867

7 January 2021

Structural biology of HIV.

1 reference

https://api.crossref.org/works/10.1038%2FNM0703-867

7 January 2021

Identifiers

DOI

10.1038/NM0703-867

1 reference

13 May 2018

PubMed ID

12835707

1 reference

13 May 2018